Biomet sales advance 10%
This article was originally published in The Gray Sheet
Executive Summary
Orthopedic device maker reports "strong" fiscal fourth-quarter revenue growth of 10% (8% at constant currency) to $702.5 million, on June 28. The preliminary results for the quarter ended May 31 include reconstructive implant sales growth of 12% to $525 million. "Biomet's performance was quite strong, and the read-through to the orthopedic group should be positive, as growth accelerated sequentially in hips, knees, trauma, extremities and dental" products, J.P. Morgan analyst Michael Weinstein said in a June 28 report. While the firm's "U.S. performance was flat sequentially," accelerated growth overseas came "despite two months of Japanese price cuts and concerns about the incremental pressures in Europe," Weinstein noted. Biomet will release its full Q4 results on July 13
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.